Fulgent Genetics (NASDAQ: FLGT) CFO has shares withheld for RSU taxes

Rhea-AI Filing Summary

Fulgent Genetics, Inc. CFO and Treasurer Paul Kim reported several tax-withholding dispositions of common stock tied to previously granted restricted stock units. On February 26 and March 1, 2026, shares were withheld at prices of $24.76 and $15.33 to cover associated tax obligations rather than open-market sales.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Kim Paul

Role CFO and Treasurer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	1,133	$15.33	$17K
Tax Withholding	Common Stock	8,347	$15.33	$128K
Tax Withholding	Common Stock	1,168	$24.76	$29K

Holdings After Transaction: Common Stock — 376,894 shares (Direct)

Footnotes (1)

1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, , which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kim Paul

(Last) (First) (Middle)

C/O FULGENT GENETICS, INC.

4399 SANTA ANITA AVENUE

(Street)

EL MONTE CA 91731

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO and Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		F		1,168(1)	D	$24.76	378,027	D
Common Stock	03/01/2026		F		1,133(2)	D	$15.33	376,894	D
Common Stock	03/01/2026		F		8,347(3)	D	$15.33	368,547	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024.

2. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, , which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022.

3. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025.

	/s/ Paul Kim	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Fulgent Genetics (FLGT) report for CFO Paul Kim?

Fulgent Genetics reported that CFO Paul Kim had shares of common stock withheld to cover tax obligations from vesting restricted stock units. These are tax-withholding dispositions under code F, not open-market purchases or sales of additional shares.

Were Paul Kim’s Fulgent Genetics (FLGT) transactions open-market stock sales?

No, the transactions were not open-market sales. Shares were withheld by the company to satisfy tax withholding obligations when previously granted restricted stock units vested, as reflected by transaction code F on the Form 4 filing.

How many Fulgent Genetics (FLGT) shares were involved in Paul Kim’s tax-withholding dispositions?

The Form 4 shows multiple small dispositions of common stock to cover taxes upon RSU vesting. Each line item reflects specific share amounts withheld rather than shares sold on the market, consistent with standard tax-withholding treatment for equity awards.

What triggered the Fulgent Genetics (FLGT) share withholdings for CFO Paul Kim?

The share withholdings were triggered by the vesting of restricted stock units previously granted to Paul Kim. Footnotes state the RSUs were granted on February 28, 2022, February 26, 2024, and February 25, 2025, and the vesting created tax obligations.

What does transaction code F mean in the Fulgent Genetics (FLGT) Form 4?

Transaction code F indicates payment of an exercise price or tax liability by delivering securities. In this case, Fulgent Genetics withheld common shares from CFO Paul Kim to satisfy tax withholding obligations when his restricted stock units vested.

Does the Fulgent Genetics (FLGT) Form 4 suggest a change in Paul Kim’s investment stance?

The Form 4 reflects tax-withholding dispositions rather than discretionary buying or selling decisions. Shares were withheld automatically to pay taxes on vesting restricted stock units, so it does not, by itself, indicate a change in Paul Kim’s investment view.